OBJECTIVE:To provide reference information for pharmacoeconomic studies in China.METHODS:To intro?duce the roles of budget impact analysis and financial impact analysis and the connection with cost-effectiveness analy?sis.RESULTS&CONCLUSION:Budget impact analysis can contribute to making innovative drug reimbursement decision.

OBJECTIVE:To explore WHO western pacific region to essential drugs available and the framework of regional action (2010～2015) and the implications of China's essential drug policy.METHODS:Discuss WHO western pacific region to essential drug available and the framework of regional action of 2010～2015,and to help WHO western pacific regional expert consultation of member states including China can obtain the essential drug which was afforded,quailty assurance,use properly,fair,and available.RESULTS & CONCLUSION:As a key member of WHO western pacific region,we support the plan and framework,but we need to do with the implementation of national conditions.

Objective: To compare utility values measured by different instruments. Methods: Different instruments were used to measure utility values in 350 patients who were diagnosed as age-related macular degeneration at the same time. The median of utility values measured by different instruments was regarded as relative standard utility value to process comparison, analysis of variance, correlation analysis and curve estimation. Results: Most differences and correlations among utility values measured by different instruments were significant, as well as equations estimated from relative standard utility value and utility values measured by different instruments, but the degree of fitting was not high. Conclusion: The utility values of the same subject measured by different instruments are quite different. The results of the study could provide correction reference to the utility value measured by single instrument in the absence of absolute standard.

OBJECTIVE:To summarize the experiences of Ningxia's drug tender policy reform in unifying tender operation,price,and distribution("Trinity" reform).METHODS:Review of the reform process with discussion from the perspective of extension of tender policy objective,essential medicine policy as well as existing problems and corresponding countermeasures.RESULTS & CONCLUSIONS:In addition to the functions that Ningxia's "Trinity" reform of drug tender policy solidifies the price-lowering role of drug tender policy and benefits the construction of essential medicine policy,the reform still needs to be improved with regards to some existing problems.

The paper undertakes a study of equity in the distribution of health resources in China by means of the Theil Index. The results indicate that equity in the distribution of hospital beds, doctors, and nurses between the various provinces is taking a turn for the better. The improvement of equity in the distribution of hospital beds and doctors is mainly due to the improvement in the eastern regions while the central and western regions still maintain the status quo, with supply basically meeting demand. The improvement of equity in the distribution of nurses, however, is due to the simultaneous improvement in the eastern, central and western regions, yet demand exceeds supply.

OBJECTIVE:To evaluate the cumulative incidence of end-stage renal disease(ESRD)in Chinese hypertensive type2diabetic patients with microalbuminuria(DHM)treated with different regimes,and to provide reference for decision makers.METHODS:A peer-reviewed Markov model that simulated progression from microalbuminuria to nephropathy,dou?bling of serum creatinine,ESRD,and all-cause mortality in patients with DHM was adapted to China.Three strategies were compared:(1)early use of irbesartan(i.e.prompt treatment in subjects with microalbuminuria);(2)late use of irebesartan(i.e.as from overt nephropathy);(3)standard hypertension care(with comparable blood pressure control).Cumulative incidence of ESRD,costs and life expectancy were projected for a hypothetical cohort of1000subjects.Treatment-specific progression and mortality probabilities were derived from published trials:IRMA-2(in microalbuminuria)and IDNT(in overt nephropathy).Medical management and cost data per state were obtained from published local sources.A flexible time horizon up to25years and third party payer perspective were used.Future costs and LE were discounted at3%yearly.RESULTS:When compared with standard blood pressure control,early use of irbesartan was evaluated to reduce the cumulative incidence of ESRD from(mean?standard deviation)8%to22%,save RMB30348(US＄3667),and add0.638life years per treated patient.Late use of irbesartan was dominant over control group but dominated by early irbesartan.Break-even occurred after13years.CON?CLUSION:Treating DHM patients by early use of irbesartan is evaluated to reduce the incidence of ESRD,extend life and reduce costs.Treating patients at a later stage is still beneficial,however to a lower extent.

OBJECTIVE:To study the relevance between the distribution of chain drug stores and medical institutions in Shanghai.METHODS:Taken the density of chain drug stores and medical institutions as index for the description of their distribution,and both non-parametric and parametric methods were applied in the relationship analysis.RESULTS:It was found that the density of chain drug stores and that of the medical institutions were in nonlinear and concaved downward re?lationship.CONCLUSION:The study suggested that currently the distribution of chain drug stores in shanghai is incongruous with the competition pressure from hospital pharmacies.

OBJECTIVE:To provide references for drug pricing and drug administration for Chinese government.METHODS:The drug pricing and administration policies in UK were expounded and the effects of which were analyzed and evaluated,based on which some suggestions were put forward with the consideration of the specific condition of our country.RESULTS&CONCLUSIONS:The rules of market economy should be obeyed and market monitoring should be carried out in China.The non-governmental organizations should play a key role in the support and service for national drug supervision and administration.The drug prices should be controlled according to category so as to make the formula process of drug price policy scientific.The government-set price and the market price monitoring mechanism should be established and the legal system of drug price management should be established as soon as possible.

OBJECTIVE:To introduce methods of cost categorizing in pharmacoeconomics evaluation and existing controversy METHODS:To compare different cost measurement methods and definition in different pharmacoeconomic guideline RESULTS & CONCLUSION:Choosing appropriate cost spectrum corresponding to different studing aspects

OBJECTIVE:To provide reference for choosing appropriate methods of health outcome measurement in phar?macoeconomic evaluation.METHODS:To compare different outcome measurement methods and introduce the standards in varied pharmacoeconomic guidelines.RESULTS&CONCLUSION:We should choose those methods according to different health systems,angles of research and disease specialities.